We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus (AGEN) Reports Narrower-than-Expected Q3 Loss
Read MoreHide Full Article
Agenus Inc.(AGEN - Free Report) is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.
The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary product platform.
With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. The company has three platform technologies for the development of its candidates – Retrocyte Display, SECANT and phage display – each designed to produce quality human antibodies. The company has several early-to-mid stage candidates in its portfolio.
Agenus’ track record has been disappointing so far. The company has surpassed estimates only once in the trailing four quarters and missed the same in all the other occasions, bringing the average negative surprise to 1.04%.
Currently, Agenus has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agenus reported narrower-than-expected loss in the third quarter of 2016. Our consensus called for a loss of 32 cents per share, while the company reported a loss of 25 cents.
Revenue: Revenues, however, missed expectations. Agenus posted revenues of $4.4 million, compared to our consensus estimate of $6 million.
Key Stats: Agenus’ efforts for the development of its pipeline are impressive. Meanwhile, GlaxoSmithKline's Shingrix vaccine candidate, containing Agenus' QS-21 Stimulon for the prevention of shingles in adults aged 50 years or older, was filed for regulatory approval in the U.S.
Check back later for our full write up on AGEN earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agenus (AGEN) Reports Narrower-than-Expected Q3 Loss
Agenus Inc.(AGEN - Free Report) is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.
The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary product platform.
With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. The company has three platform technologies for the development of its candidates – Retrocyte Display, SECANT and phage display – each designed to produce quality human antibodies. The company has several early-to-mid stage candidates in its portfolio.
Agenus’ track record has been disappointing so far. The company has surpassed estimates only once in the trailing four quarters and missed the same in all the other occasions, bringing the average negative surprise to 1.04%.
Currently, Agenus has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agenus reported narrower-than-expected loss in the third quarter of 2016. Our consensus called for a loss of 32 cents per share, while the company reported a loss of 25 cents.
Revenue: Revenues, however, missed expectations. Agenus posted revenues of $4.4 million, compared to our consensus estimate of $6 million.
Key Stats: Agenus’ efforts for the development of its pipeline are impressive. Meanwhile, GlaxoSmithKline's Shingrix vaccine candidate, containing Agenus' QS-21 Stimulon for the prevention of shingles in adults aged 50 years or older, was filed for regulatory approval in the U.S.
AGENUS INC Price
AGENUS INC Price | AGENUS INC Quote
Check back later for our full write up on AGEN earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>